The Korea Pharmaceutical and Bio-Pharma Manufacturers Association and the state-run Korea Trade-Investment Promotion Agency said Thursday that they have signed a Memorandum of Understanding agreeing to such terms.
|KPBMA Chairman Won Hee-mok (left) and KOTRA CEO Kim Jae-hong pose after signing a memorandum of understanding at the KOTRA headquarters in Seoul, Wednesday. (KPBMA)|
Under the memorandum, the two entities will work to provide support to local pharma companies in scoring more investment from overseas investors, as well as become a channel for information exchange in the sector on a global level.
“That Korean companies account for only a small portion of the global pharmaceutical market, despite its strengths, suggests there is room for further growth,” said KPBMA Chairman Won Hee-mok.“We hope that this MOU will become an important turning point in advancing Korea’s pharma sector.”
“By Merging KOTRA’s strength in exports and investments with the KPBMA’s pharma business expertise, we hope to help accelerate Korean firms’ foray into global markets,” said KOTRA CEO Kim Jae-hong.
By Sohn Ji-young (firstname.lastname@example.org)